Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06180421 · ClinicalTrials.gov registry record
Mitochondrial Video Assessment Source Material Study
A clinical trial, sponsored by The Emmes Company.
- Completed
- Registry status
- 28
- Enrollment target
NCT06180421: Completed study, sponsored by The Emmes Company.
NCT06180421 is a clinical trial that has completed, run by The Emmes Company. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06180421 has completed, sponsored by The Emmes Company.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
Source material collection of videos to develop the Mitochondrial Video Assessment (MVA) for patients with mitochondrial myopathies.
Primary Outcome
Initiate feasibility testing and collect source material videos from patients with Primary Mitochondrial Myopathy (PMM, n=35) or a PolGamma (PolG) mutation (n=15) to facilitate development of the Mitochondrial Video Assessment (MVA).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-06-16 |
| Est. Completion | 2024-02-02 |
What the finished NCT06180421 record still lists
NCT06180421 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT06180421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06180421 about?
NCT06180421 is a clinical study titled "Mitochondrial Video Assessment Source Material Study". Source material collection of videos to develop the Mitochondrial Video Assessment (MVA) for patients with mitochondrial myopathies.
What is the current status of trial NCT06180421?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2023-06-16. Estimated completion is 2024-02-02.
Who is sponsoring clinical trial NCT06180421?
This trial is sponsored by The Emmes Company, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI